Argenx SE Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

AI Briefing

• – Argenx SE presents new data on VYVGART's efficacy in multiple sclerosis and chronic inflammatory demyelinating polyneuropathy at AAN 2026.
• – New data supports expanded use of VYVGART in both multiple sclerosis and chronic inflammatory demyelinating polyneuropathy.
• – Argenx SE presents positive results of Phase 3 trial on VYVGART for multiple sclerosis and CIDP.